<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Zai Lab Ltd ( (HK:9688) ) has shared an update. Zai Lab Limited has granted share options and restricted share units under its 2024 Equity Incentive Plan, issuing 136,819 American depositary shares in options to a single employee and 75,288 ADS-equivalent restricted share units to four employees. The awards, which carry a 10-year option term and four-year vesting schedule without performance targets or clawback provisions, are designed to align employee incentives with long-term shareholder interests and maintain market-competitive compensation. The stock options are priced at US$20.32 per ADS, slightly above the ADS closing price of US$19.59 on the grant date, while the restricted share units are granted at no purchase price. By expanding equity-based compensation, Zai Lab aims to strengthen employee retention and reinforce its talent strategy, which may support execution of its growth plans and enhance alignment between management and investors as the company navigates the global biopharmaceutical market. The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page. More about Zai Lab Ltd Zai Lab Limited is a biopharmaceutical company listed in Hong Kong and the U.S., focused on developing and commercializing innovative medicines. The company operates through a global equity incentive framework to attract and retain specialized talent in the competitive healthcare and life sciences sector. Average Trading Volume: 11,022,162 Technical Sentiment Signal: Sell Current Market Cap: HK$17.08B For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.</div>

ZLAB

ARKG

LABU

Zai Lab Ltd has granted share options and restricted share units under its 2024 Equity Incentive Plan, issuing 136,819 American depositary shares in options to one employee and 75,288 ADS-equivalent restricted share units to four employees. The options have a 10-year term and a four-year vesting schedule, priced at US$20.32 per ADS. This initiative aims to align employee incentives with shareholder interests and enhance talent retention as the company navigates the biopharmaceutical market. The current analyst rating for Zai Lab stock is a Hold with a price target of HK$18.00.

- Zai Lab Ltd has issued 136,819 share options and 75,288 restricted share units to employees under its 2024 Equity Incentive Plan.  
- The options are priced at US$20.32 per American depositary share, just above the closing price of US$19.59, with a 10-year term and four-year vesting.  
- This initiative aims to enhance employee retention, align management with shareholder interests, and support Zai Lab's growth in the global biopharmaceutical market.

Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan